Overall, the positive therapeutic outcomes generated when assessing CuII(atsm) in mutant SOD1 mouse models of ALS include: improved motor function; neuroprotection; increased survival; return to disease progression upon treatment removal; dose-proportional disease modification; better therapeutic efficacy than riluzole when compared head-to-head; suitability for co-administration with riluzole; and strong disease-modification when treatments commenced after overt motor symptom onset. Here, SOD1 is linked to amyotrophic lateral sclerosis.